Nowadays, there's lots of buzz about spectacular new medical treatments such as personalised cancer therapy with modified immune cells or antibodies. Such treatments, however, are very complex and expensive and so find only limited application. Most medical therapies are still based on small chemical compounds that can be produced in large quantities and thus at low cost.
The bottleneck in the development of new molecular therapies is the limited number of new active substances that can be found using current techniques. A method developed in the 2000s at Harvard and ETH Zurich promises to provide a remedy: DNA-encoded chemical libraries (DEL).
Nowadays, there's lots of buzz about spectacular new medical treatments such as personalised cancer therapy with modified immune cells or antibodies. Such treatments, however, are very complex and expensive and so find only limited application. Most medical therapies are still based on small chemical compounds that can be produced in large quantities and thus at low cost.
The bottleneck in the development of new molecular therapies is the limited number of new active substances that can be found using current techniques. A method developed in the 2000s at Harvard and ETH Zurich promises to provide a remedy: DNA-encoded chemical libraries (DEL).
